exRNAdisease

General Information

Database ID:

exR0080658

RNA Name:

RPS27A

RNA Type:

mRNA

Chromosome:

chr2

Starnd:

Coordinate:

Start Site(bp):

55231903

End Site(bp):

55235853

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABCF2	chr7	151207837	151227166	-
ABHD2	chr15	89087459	89202355	+
ABRACL	chr6	139028745	139043302	+
AC068946.1	chr2	219075329	219170827	-
AC091167.2	chr15	90249556	90272208	+
AC245033.1	chr15	82536788	82573194	-
ACAD8	chr11	134253495	134265855	+
ACLY	chr17	41866917	41930542	-
ACTB	chr7	5527148	5563784	-
ACTG1	chr17	81509971	81523847	-
ACTR2	chr2	65227753	65271253	+
ACVR1	chr2	157736444	157876330	-
ADAR	chr1	154582057	154628013	-
ADD1	chr4	2843857	2930076	+
ADORA2A	chr22	24417879	24442357	+
ADSL	chr22	40346500	40390463	+
AGAP1	chr2	235494043	236131800	+
AGPAT4	chr6	161129967	161274061	-
AGTPBP1	chr9	85546539	85742029	-
AHNAK	chr11	62433542	62556235	-
AIF1L	chr9	131096476	131123152	+
AL022238.4	chr22	40346529	40410054	+
AL133352.1	chr10	100505628	100529881	-
AL136454.1	chr1	192716132	192716653	+
AL139300.1	chr14	103562962	103685924	+
AL355315.1	chr10	97584374	97673910	+
ALDH7A1	chr5	126531200	126595362	-

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-4426	chr1	192716333	192716349	+
hsa-miR-4485-3p	chr11	10508277	10508296	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC016876.2	chr17	7581964	7584086	-
AC091564.7	chr11	6610883	6616594	-
AC104257.1	chr8	131308545	131317632	+
AC106864.1	chr4	112693047	112706810	-
AC239868.1	chr1	149861271	149862504	+
AC245033.4	chr15	82533175	82540008	-
AL031656.1	chr20	42685404	42688562	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference